Annovis Bio to Host Webcast on June 24, 2025, Featuring Updates on Phase 3 AD Trial and PD Program Development

Annovis Bio

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced a live webcast with Maria Maccecchini, Ph.D., President and CEO, to provide updates and answer audience questions.

Webcast Details

Dr. Maccecchini will discuss progress on the pivotal Phase 3 trial in early AD, the FDA’s feedback on the PD program, and other key updates. The event includes a brief presentation and live Q&A, giving attendees a chance to engage directly with the CEO.

The webcast is open to shareholders, patients, investigators, and anyone interested in Annovis’ work and direction. Submit questions in advance by emailing ir@annovisbio.com.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.

READ:  Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment